Caplin Point Laboratories Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 28, 2025, 7:48 am

Competitors of Caplin Point Laboratories Ltd

All Competitor Stocks of Caplin Point Laboratories Ltd

Quarterly Result

Last Updated: August 20, 2025, 12:25 pm

Below is a detailed analysis of the quarterly data for Caplin Point Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 510.00 Cr.. The value appears strong and on an upward trend. It has increased from 502.00 Cr. (Mar 2025) to 510.00 Cr., marking an increase of 8.00 Cr..
• For Expenses, as of Jun 2025, the value is 332.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 334.00 Cr. (Mar 2025) to 332.00 Cr., marking a decrease of 2.00 Cr..
• For Operating Profit, as of Jun 2025, the value is 178.00 Cr.. The value appears strong and on an upward trend. It has increased from 168.00 Cr. (Mar 2025) to 178.00 Cr., marking an increase of 10.00 Cr..
• For OPM %, as of Jun 2025, the value is 35.00%. The value appears strong and on an upward trend. It has increased from 33.00% (Mar 2025) to 35.00%, marking an increase of 2.00%.
• For Other Income, as of Jun 2025, the value is 23.00 Cr.. The value appears to be declining and may need further review. It has decreased from 26.00 Cr. (Mar 2025) to 23.00 Cr., marking a decrease of 3.00 Cr..
• For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
• For Depreciation, as of Jun 2025, the value is 16.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 17.00 Cr. (Mar 2025) to 16.00 Cr., marking a decrease of 1.00 Cr..
• For Profit before tax, as of Jun 2025, the value is 184.00 Cr.. The value appears strong and on an upward trend. It has increased from 177.00 Cr. (Mar 2025) to 184.00 Cr., marking an increase of 7.00 Cr..
• For Tax %, as of Jun 2025, the value is 18.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 18.00%.
• For Net Profit, as of Jun 2025, the value is 151.00 Cr.. The value appears strong and on an upward trend. It has increased from 145.00 Cr. (Mar 2025) to 151.00 Cr., marking an increase of 6.00 Cr..
• For EPS in Rs, as of Jun 2025, the value is 20.10. The value appears strong and on an upward trend. It has increased from 18.76 (Mar 2025) to 20.10, marking an increase of 1.34.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: November 15, 2025, 5:35 am

Growth

Last Updated: September 5, 2025, 1:35 am

Balance Sheet

Last Updated: November 9, 2025, 1:48 pm

Below is a detailed analysis of the balance sheet data for Caplin Point Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

• For Equity Capital, as of Sep 2025, the value is 15.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 15.00 Cr..
• For Reserves, as of Sep 2025, the value is 3,144.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,619.00 Cr. (Mar 2025) to 3,144.00 Cr., marking an increase of 525.00 Cr..
• For Borrowings, as of Sep 2025, the value is 5.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 222.00 Cr. (Mar 2025) to 5.00 Cr., marking a decrease of 217.00 Cr..
• For Other Liabilities, as of Sep 2025, the value is 339.00 Cr.. The value appears to be improving (decreasing). It has decreased from 352.00 Cr. (Mar 2025) to 339.00 Cr., marking a decrease of 13.00 Cr..
• For Total Liabilities, as of Sep 2025, the value is 3,504.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,208.00 Cr. (Mar 2025) to 3,504.00 Cr., marking an increase of 296.00 Cr..
• For Fixed Assets, as of Sep 2025, the value is 555.00 Cr.. The value appears strong and on an upward trend. It has increased from 546.00 Cr. (Mar 2025) to 555.00 Cr., marking an increase of 9.00 Cr..
• For CWIP, as of Sep 2025, the value is 177.00 Cr.. The value appears strong and on an upward trend. It has increased from 144.00 Cr. (Mar 2025) to 177.00 Cr., marking an increase of 33.00 Cr..
• For Investments, as of Sep 2025, the value is 636.00 Cr.. The value appears strong and on an upward trend. It has increased from 590.00 Cr. (Mar 2025) to 636.00 Cr., marking an increase of 46.00 Cr..
• For Other Assets, as of Sep 2025, the value is 2,135.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,928.00 Cr. (Mar 2025) to 2,135.00 Cr., marking an increase of 207.00 Cr..
• For Total Assets, as of Sep 2025, the value is 3,504.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,208.00 Cr. (Mar 2025) to 3,504.00 Cr., marking an increase of 296.00 Cr..

Notably, the Reserves (3,144.00 Cr.) exceed the Borrowings (5.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Mutual Fund Holdings

Key Financial Ratios

After reviewing the key financial ratios for Caplin Point Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 70.57. This value is within the healthy range. It has increased from 60.19 (Mar 24) to 70.57, marking an increase of 10.38.
• For Diluted EPS (Rs.), as of Mar 25, the value is 70.25. This value is within the healthy range. It has increased from 59.90 (Mar 24) to 70.25, marking an increase of 10.35.
• For Cash EPS (Rs.), as of Mar 25, the value is 79.88. This value is within the healthy range. It has increased from 67.79 (Mar 24) to 79.88, marking an increase of 12.09.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 365.25. It has increased from 299.18 (Mar 24) to 365.25, marking an increase of 66.07.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 365.25. It has increased from 299.18 (Mar 24) to 365.25, marking an increase of 66.07.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 254.93. It has increased from 223.05 (Mar 24) to 254.93, marking an increase of 31.88.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 97.81. This value is within the healthy range. It has increased from 81.42 (Mar 24) to 97.81, marking an increase of 16.39.
• For PBIT / Share (Rs.), as of Mar 25, the value is 89.13. This value is within the healthy range. It has increased from 74.38 (Mar 24) to 89.13, marking an increase of 14.75.
• For PBT / Share (Rs.), as of Mar 25, the value is 89.05. This value is within the healthy range. It has increased from 74.32 (Mar 24) to 89.05, marking an increase of 14.73.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 71.20. This value is within the healthy range. It has increased from 60.75 (Mar 24) to 71.20, marking an increase of 10.45.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 70.57. This value is within the healthy range. It has increased from 60.18 (Mar 24) to 70.57, marking an increase of 10.39.
• For PBDIT Margin (%), as of Mar 25, the value is 38.36. This value is within the healthy range. It has increased from 36.50 (Mar 24) to 38.36, marking an increase of 1.86.
• For PBIT Margin (%), as of Mar 25, the value is 34.96. This value exceeds the healthy maximum of 20. It has increased from 33.34 (Mar 24) to 34.96, marking an increase of 1.62.
• For PBT Margin (%), as of Mar 25, the value is 34.93. This value is within the healthy range. It has increased from 33.31 (Mar 24) to 34.93, marking an increase of 1.62.
• For Net Profit Margin (%), as of Mar 25, the value is 27.92. This value exceeds the healthy maximum of 10. It has increased from 27.23 (Mar 24) to 27.92, marking an increase of 0.69.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is 27.68. This value exceeds the healthy maximum of 20. It has increased from 26.98 (Mar 24) to 27.68, marking an increase of 0.70.
• For Return on Networth / Equity (%), as of Mar 25, the value is 19.32. This value is within the healthy range. It has decreased from 20.39 (Mar 24) to 19.32, marking a decrease of 1.07.
• For Return on Capital Employeed (%), as of Mar 25, the value is 23.34. This value is within the healthy range. It has decreased from 23.86 (Mar 24) to 23.34, marking a decrease of 0.52.
• For Return On Assets (%), as of Mar 25, the value is 16.71. This value is within the healthy range. It has decreased from 16.94 (Mar 24) to 16.71, marking a decrease of 0.23.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has decreased from 0.69 (Mar 24) to 0.65, marking a decrease of 0.04.
• For Current Ratio (X), as of Mar 25, the value is 6.97. This value exceeds the healthy maximum of 3. It has increased from 5.71 (Mar 24) to 6.97, marking an increase of 1.26.
• For Quick Ratio (X), as of Mar 25, the value is 5.88. This value exceeds the healthy maximum of 2. It has increased from 4.62 (Mar 24) to 5.88, marking an increase of 1.26.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.54. This value is within the healthy range. It has increased from 0.73 (Mar 24) to 5.54, marking an increase of 4.81.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 7.47 (Mar 24) to 0.00, marking a decrease of 7.47.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 6.69 (Mar 24) to 0.00, marking a decrease of 6.69.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 92.53 (Mar 24) to 0.00, marking a decrease of 92.53.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 93.31 (Mar 24) to 0.00, marking a decrease of 93.31.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 1,218.62. This value is within the healthy range. It has increased from 792.79 (Mar 24) to 1,218.62, marking an increase of 425.83.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 888.05. This value is within the healthy range. It has increased from 592.22 (Mar 24) to 888.05, marking an increase of 295.83.
• For Enterprise Value (Cr.), as of Mar 25, the value is 14,664.80. It has increased from 9,483.55 (Mar 24) to 14,664.80, marking an increase of 5,181.25.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 7.57. This value exceeds the healthy maximum of 3. It has increased from 5.60 (Mar 24) to 7.57, marking an increase of 1.97.
• For EV / EBITDA (X), as of Mar 25, the value is 19.73. This value exceeds the healthy maximum of 15. It has increased from 15.34 (Mar 24) to 19.73, marking an increase of 4.39.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 7.86. This value exceeds the healthy maximum of 3. It has increased from 5.91 (Mar 24) to 7.86, marking an increase of 1.95.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 92.52 (Mar 24) to 0.00, marking a decrease of 92.52.
• For Price / BV (X), as of Mar 25, the value is 5.48. This value exceeds the healthy maximum of 3. It has increased from 4.46 (Mar 24) to 5.48, marking an increase of 1.02.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 7.86. This value exceeds the healthy maximum of 3. It has increased from 5.91 (Mar 24) to 7.86, marking an increase of 1.95.
• For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness